Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Questioning the benefits of statins

Garey Mazowita
CMAJ November 08, 2005 173 (10) 1210; DOI: https://doi.org/10.1503/cmaj.1050121
Garey Mazowita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The recently published controversy on the 2003 Canadian dyslipidemia guidelines1,2,3 should be cause for some reflection on the utility of guidelines. The back-and-forth dialogue was reminiscent of what does, or should, occur daily in the offices of Canada's family physicians.

Family doctors see patients with various values, resources, education levels, motivations, fears, preferences, degrees of risk aversion and levels of understanding. Their task is to define treatment goals consistent with all these patient attributes and then base management decisions on those goals. Guidelines, where available, should contribute to the discussion but should rarely be the sole determinant of a patient's treatment goals. Just as from a population health perspective we must weigh benefit with cost and lost opportunity, so must we do with each individual. Guidelines must inform us but should not necessarily compel us.

Unfortunately, as our primary care system comes under more and more stress, the family physician's ability to discuss individual treatment goals, as opposed to simply applying guidelines, is diminished. It is easier to titrate a drug to a guideline or laboratory end point. Furthermore, achievement of such end points is often easily measured and therefore this goal is attractive to administrators. This may not, however, be best for patients when evaluated in the context of treatment goals, population outcomes and system costs.

REFERENCES

  1. 1.↵
    Manuel DG, Tanuseputro P, Mustard CA, et al. The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed [editorial]. CMAJ 2005;172(8):1027-31.
    OpenUrlFREE Full Text
  2. 2.↵
    Genest J, McPherson R, Frohlich J, et al. The analysis by Manuel and colleagues creates controversy with headlines, not data [editorial]. CMAJ 2005;172(8):1033-4.
    OpenUrlFREE Full Text
  3. 3.↵
    Manuel DG, Tanuseputro P, Mustard CA, et al. Rebuttal [editorial]. CMAJ 2005;172(8):1037.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 173 (10)
CMAJ
Vol. 173, Issue 10
8 Nov 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Questioning the benefits of statins
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Questioning the benefits of statins
Garey Mazowita
CMAJ Nov 2005, 173 (10) 1210; DOI: 10.1503/cmaj.1050121

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Questioning the benefits of statins
Garey Mazowita
CMAJ Nov 2005, 173 (10) 1210; DOI: 10.1503/cmaj.1050121
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • REFERENCES
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • An expanded role for blood donor emerging pathogens surveillance
  • Beyond wastewater surveillance: refining environmental pathogen detection in the built environment
  • Observational evidence in support of screening for depression during pregnancy and the postpartum period
Show more Letters

Similar Articles

Collections

  • Topics
    • Cardiovascular medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire